Clinical, economic, and humanistic burden of community acquired pneumonia in Europe: a systematic literature review

被引:28
作者
Tsoumani, Eleana [1 ]
Carter, John A. [2 ]
Salomonsson, Stina [3 ]
Stephens, Jennifer M. [2 ]
Bencina, Goran [4 ]
机构
[1] MSD Ctr Observat & Real World Evidence, Alimos, Greece
[2] OPEN Hlth Evidence & Access, Bethesda, MD 20814 USA
[3] MSD Ctr Observat & Real World Evidence, Stockholm, Sweden
[4] MSD Ctr Observat & Real World Evidence, Madrid, Spain
关键词
Community acquired pneumonia; disease burden; Europe; economic; epidemiology; quality of life; RISK-FACTORS; PNEUMOCOCCAL VACCINATION; COST-EFFECTIVENESS; ADULTS; PATHOGENS;
D O I
10.1080/14760584.2023.2261785
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Community-acquired pneumonia (CAP) is an infectious lung inflammation contracted outside the hospital. CAP is a leading cause of death among young children, elderly, and immunocompromised persons. Incidence can reach 14 cases/1,000 adults. Up to 50% of cases require inpatient hospitalization. Mortality is 0.7/1,000 cases or 4 million deaths per year. We sought to summarize multi-dimensional burden of CAP for selected European countries.Methods We conducted a systematic literature review of literature published from 2011 to 2021 whereby we sought information pertaining to the epidemiologic, clinical, economic, and humanistic burden of CAP. Findings were summarized descriptively.Results CAP incidence in Europe is variable, with the highest burden among those of advanced age and with chronic comorbidities. Etiology is primarily bacterial infection with Streptococcus pneumoniae being the most frequently implicated. Direct medical costs are primarily attributable to inpatient stay, which is exacerbated among high-risk populations. Higher mortality rates are associated with increasing age, the need for inpatient hospitalization, and antibiotic resistance.Conclusions A better understanding of CAP is needed, specifically the economic and quality of life burden on patients and caregivers. We recommend further assessments using population-level and real-world data employing consistent disease definitions.
引用
收藏
页码:876 / 884
页数:9
相关论文
共 37 条
[1]   Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective [J].
Aliberti, Stefano ;
Cilloniz, Catia ;
Chalmers, James D. ;
Zanaboni, Anna Maria ;
Cosentini, Roberto ;
Tarsia, Paolo ;
Pesci, Alberto ;
Blasi, Francesco ;
Torres, Antoni .
THORAX, 2013, 68 (11) :997-999
[2]   Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe [J].
Alimi, Y. ;
Lim, W. S. ;
Lansbury, L. ;
Leonardi-Bee, J. ;
Nguyen-Van-Tam, J. S. .
JOURNAL OF CLINICAL VIROLOGY, 2017, 95 :26-35
[3]   Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational Studies [J].
Almirall, Jordi ;
Serra-Prat, Mateu ;
Bolibar, Ignasi ;
Balasso, Valentina .
RESPIRATION, 2017, 94 (03) :299-311
[4]   Health related quality of life in patients with community-acquired pneumococcal pneumonia in France [J].
Andrade, Luiz Flavio ;
Saba, Grece ;
Ricard, Jean-Damien ;
Messika, Jonathan ;
Gaillat, Jacques ;
Bonnin, Pierre ;
Chidiac, Christian ;
Illes, Hajnal-Gabriela ;
Laurichesse, Henri ;
Detournay, Bruno ;
Petitpretz, Patrick ;
de Pouvourville, Gerard .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2018, 16
[5]   Hospitalization direct cost of adults with community-acquired pneumonia in Portugal from 2000 to 2009 [J].
Antunes, C. ;
Pereira, M. ;
Rodrigues, L. ;
Organista, D. ;
Cysneiros, A. ;
Paula, F. ;
Nunes, B. ;
Barbosa, P. ;
Barbara, C. ;
Escoval, A. ;
Diniz, A. ;
Froes, F. .
PULMONOLOGY, 2020, 26 (05) :264-267
[6]  
Bai FS, 2021, IRAN J PUBLIC HEALTH, V50, P1108, DOI 10.18502/ijph.v50i6.6410
[7]   The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia [J].
Blanc, E. ;
Chaize, G. ;
Fievez, S. ;
Feger, C. ;
Herquelot, E. ;
Vainchtock, A. ;
Timsit, J. F. ;
Gaillat, J. .
BMC INFECTIOUS DISEASES, 2021, 21 (01)
[8]   Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy [J].
Boccalini, Sara ;
Bechini, Angela ;
Levi, Miriam ;
Tiscione, Emila ;
Gasparini, Roberto ;
Bonanni, Paolo .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (03) :699-706
[9]  
Canadian Agency for Drugs and Technologies in Health, Strings attached: CADTH's database search filters
[10]   Community-acquired pneumonia in the United Kingdom: a call to action [J].
James Chalmers ;
James Campling ;
Gillian Ellsbury ;
Peter M. Hawkey ;
Harish Madhava ;
Mary Slack .
Pneumonia, 9 (1)